Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PhenoSwitch Bioscience is a contract research organization (CRO) specializing in high-performance mass spectrometry services for the life sciences and biopharmaceutical sectors. Based in Sherbrooke, Canada, the company provides advanced analytical solutions including proteomics, metabolomics, lipidomics, and bioanalysis to accelerate drug discovery and development. Their expertise encompasses biomarker discovery, protein characterization, and custom assay development using state-of-the-art LC-MS/MS technology. In May 2024, PhenoSwitch Bioscience was acquired by Nautilus Biotechnology to integrate its mass spectrometry capabilities with Nautilus's next-generation proteome analysis platform.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PhenoSwitch Bioscience.